Pulse Biosciences: announces partnership with Clayman Thyroid Center

What happened Pulse Biosciences, Inc. announced entering into certain agreements with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, and its affiliates on Oct 14, 2026. The agreements "together form a commercial and clinical partnership between them to explore the clinical utility of the Company's proprietary nPulse Vybrance Percutaneous Electrode System," the filing states. A press release about the matters is attached as Exhibit 99.1.

Key details

• Filing date: Oct 14, 2026; the company filed the information under Item 8.01 (Other events).
• Parties: Pulse Biosciences, Inc. and the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, and its affiliates.
• Purpose: to form a commercial and clinical partnership to explore the clinical utility of the nPulse Vybrance Percutaneous Electrode System.
• Exhibit: Press release dated Oct 14, 2026 is attached as Exhibit 99.1.

Why it may matter The filing reports Item 8.01 (Other events), which covers events the company chose to disclose outside the regular periodic reports; here the company announced agreements creating a commercial and clinical partnership to explore its nPulse Vybrance Percutaneous Electrode System. A filing does not show why the insider traded or why the company acted.